Latest Leverage News

Matsa Resources has reported a strong finish to Campaign 2 at its Devon Pit Gold Mine, doubling gold production and generating nearly $29 million in sales. Campaign 3 mining is now underway, signalling continued momentum.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

ABx Group has discovered new high-extraction ionic rare earth zones at its Deep Leads project in Tasmania, accelerating the path to production within months of approval. This breakthrough enhances the project's commercial viability with rare earths critical for green technologies.

Ridley Corporation has revealed its FY26–28 Growth Plan, spotlighting earnings growth driven by its recent fertiliser acquisition and operational efficiencies across its agricultural inputs and feed segments. The company aims to leverage its market leadership and diversified portfolio to capitalise on rising demand in Australian agriculture.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Novo Resources Corp. has issued a prospectus offering free New Options to recent placement participants and joint lead managers, aiming to support its exploration projects in Western Australia and Victoria. The options, exercisable at A$0.15 and expiring in three years, could raise significant capital upon exercise, subject to shareholder approval.

Energy World Corporation appoints Alan Jowell as Executive Chairman to spearhead its strategic review and project development, while exploring asset sales alongside its flagship Pagbilao LNG and Power Project.

Hubify has provided detailed terms of its $250,000 equity investment in Australian AI firm HubLab, reinforcing its AI-first growth ambitions targeting enterprise and government sectors.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

The South Australian Court of Appeal has overturned a 2023 government proclamation, returning the Bird in Hand Gold deposit to Terramin’s exploration licence and reshaping the company’s exploration prospects.